List of Excipients in Branded Drug TESTOSTERONE CYPIONATE

Generic Drugs Containing TESTOSTERONE CYPIONATE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	testosterone cypionate	0143-9005	BENZYL ALCOHOL
Hikma Pharmaceuticals USA Inc	testosterone cypionate	0143-9005	BENZYL BENZOATE
Hikma Pharmaceuticals USA Inc	testosterone cypionate	0143-9005	COTTONSEED OIL
West-Ward Pharmaceuticals Corp	testosterone cypionate	0143-9659	BENZYL ALCOHOL
West-Ward Pharmaceuticals Corp	testosterone cypionate	0143-9659	BENZYL BENZOATE
West-Ward Pharmaceuticals Corp	testosterone cypionate	0143-9659	COTTONSEED OIL

What are the Most Frequently-Used Excipients in TESTOSTERONE CYPIONATE?

# Of NDCs	Excipient
51	BENZYL ALCOHOL
51	BENZYL BENZOATE
4	COTTON SEED
1	COTTONSEED ACID
46	COTTONSEED OIL

Testosterone Cypionate Excipient Strategy and Commercial Opportunities

Last updated: September 25, 2026

Testosterone cypionate is an established oil-based injectable with limited active-ingredient patent protection and substantial generic competition. The strongest commercial opportunities are not in the testosterone cypionate molecule itself. They are in safer excipient systems, lower-viscosity formulations, subcutaneous delivery, ready-to-use packaging, preservative-free products, and differentiated depot-release profiles.

The reference product, Depo-Testosterone, uses testosterone cypionate in an oil vehicle with benzyl benzoate. Its long commercial history leaves little scope for conventional composition-of-matter exclusivity. A new product would need to establish a clinically meaningful advantage, manufacturing benefit, or regulatory distinction.

What is the FDA status of testosterone cypionate injection?

Testosterone cypionate injection is an FDA-approved androgen replacement product administered primarily by intramuscular injection. The reference product is Depo-Testosterone, marketed by Pfizer under NDA 005286. FDA-approved use includes testosterone replacement in males with deficiency or absence of endogenous testosterone, subject to the product label and diagnostic requirements.[1]

Attribute	Testosterone cypionate
Active ingredient	Testosterone cypionate
Dosage form	Sterile injectable oil solution
Common strengths	100 mg/mL and 200 mg/mL
Primary route	Intramuscular
Typical dosing interval	Commonly every 1 to 4 weeks, depending on dose and patient response
U.S. controlled-substance status	Schedule III
Reference product	Depo-Testosterone
Reference NDA	005286
FDA pathway for generics	Abbreviated New Drug Application, or ANDA
Biosimilar pathway	Not applicable
Main formulation constraint	Poor water solubility and need for sterile oily depot delivery

Testosterone cypionate is not a biologic. Biosimilar approval is therefore irrelevant. Competitive entry is generally based on an ANDA for a pharmaceutically equivalent product or on a 505(b)(2) application for a differentiated formulation or delivery system.

What excipients are used in testosterone cypionate injections?

The established excipient system is an oil vehicle combined with a co-solvent. The reference product label identifies cottonseed oil and benzyl benzoate as inactive ingredients.[1]

Excipient or excipient class	Function	Commercial and technical considerations
Cottonseed oil	Primary vehicle and depot medium	Familiar regulatory history; potential supply, allergen-perception, and oxidation-control issues
Benzyl benzoate	Co-solvent and viscosity-modifying solvent	Helps maintain testosterone cypionate solubility; local tolerability and injection discomfort require evaluation
Sesame oil	Alternative vehicle used in some testosterone products	Established injectable use; sesame allergy and oxidation control require assessment
Benzyl alcohol	Preservative in selected multidose products	Can cause local irritation; suitability depends on container configuration and target population
Medium-chain triglycerides	Alternative lipid vehicle	May support lower viscosity or different release behavior; regulatory precedent must be assessed
Ethyl oleate	Solvent and vehicle option	May improve solubility and injection characteristics; compatibility and oxidation data are required
Refined vegetable oils	Depot vehicle	Can support product differentiation but require tight control of fatty-acid profile, peroxide value, and impurities

Excipients must be suitable for parenteral use and supported by compatibility, sterility, endotoxin, particulate, extractables, leachables, and stability data. The FDA Inactive Ingredient Database can support precedent analysis, but precedent in another injectable does not remove the need to justify concentration, route, dose, and patient exposure.[2]

Which excipient strategies can differentiate testosterone cypionate?

The most credible strategies address pain, injection volume, storage, dose consistency, and administration convenience.

Lower-viscosity oil systems

Testosterone cypionate injections can be difficult to draw and inject because oil vehicles are more viscous than aqueous solutions. A lower-viscosity vehicle could improve:

• Syringe fill time
• Needle gauge options
• Injection force
• Patient or caregiver handling
• Suitability for subcutaneous administration
• Compatibility with autoinjectors

A lower-viscosity product must preserve solubility at the intended testosterone concentration. Reducing viscosity by adding solvent can increase local irritation, alter depot behavior, or create precipitation during storage. The commercial value is highest if the formulation supports a smaller needle or reliable self-administration.

Alternative oil vehicles

Cottonseed oil is established, but alternative vehicles could address supply resilience, allergy concerns, or formulation performance. Candidate systems include sesame oil, medium-chain triglycerides, and ethyl oleate. A replacement vehicle is unlikely to secure strong protection by itself unless it produces a measurable technical or clinical result.

Relevant comparative endpoints include:

• Testosterone cypionate solubility
• Viscosity at 20 to 25°C
• Precipitation after temperature cycling
• Injection force
• Local tissue reaction
• Release profile
• Oxidative stability
• Container closure compatibility

Preservative-free single-dose presentation

Preservative-free vials, prefilled syringes, and cartridges can reduce exposure to benzyl alcohol or other antimicrobial preservatives. This strategy is commercially relevant for patients receiving repeated injections and for products intended for home administration.

A single-dose product may carry higher packaging and fill-finish costs. The value proposition improves when the product reduces preparation steps, minimizes dosing errors, and supports a premium channel such as specialty pharmacy or direct-to-patient distribution.

Benzyl-benzoate-reduced formulations

Benzyl benzoate contributes to solubility and formulation robustness, but it can also contribute to injection-site discomfort. A formulation that reduces or eliminates benzyl benzoate would require evidence that testosterone cypionate remains dissolved through shelf life and normal temperature excursions.

The patentability position improves if the formulation combines a defined solvent ratio with a specific concentration, viscosity range, stability profile, or delivery device. A generic claim to "testosterone cypionate in an oil" would face substantial prior-art risk.

Depot-release engineering

The ester itself provides prolonged release after intramuscular injection. Formulators can seek additional control through:

• Vehicle polarity
• Oil viscosity
• Solvent concentration
• Particle or crystal-state control
• Injection volume
• Route of administration
• Depot-forming excipients

A release profile that reduces peak-to-trough fluctuations could support a 505(b)(2) strategy. The sponsor would need clinical pharmacokinetic data showing a relevant improvement over approved testosterone cypionate products.

What patents protect testosterone cypionate products?

The testosterone cypionate molecule is an old androgen ester, and foundational composition-of-matter protection has expired. The commercial market is therefore driven by generic manufacturing, regulatory compliance, supply reliability, and product differentiation rather than by a live base-molecule patent.

The current U.S. patent position should be assessed through the FDA Orange Book and USPTO records for each listed product and applicant.[3,4]

Patent category	Relevance to testosterone cypionate
Composition-of-matter patents	Historical protection; expired
Basic injectable composition patents	Generally vulnerable to prior-art challenges because oil solutions are longstanding
Excipient-ratio patents	Potentially available if supported by unexpected stability, tolerability, or pharmacokinetic results
Device patents	Potentially valuable for prefilled syringes, autoinjectors, cartridges, and needle systems
Method-of-use patents	Possible for specific dosing populations or administration methods, but enforceability depends on claim scope and labeling
Manufacturing patents	Potential value for impurity control, sterilization, filling, crystallization, or high-concentration production
Orange Book-listed patents	Must be checked against the specific NDA or 505(b)(2) product; generic testosterone cypionate products generally compete without a meaningful blocking estate

An excipient patent is strongest when it claims a defined formulation window tied to a measurable performance result. Examples include a concentration range that prevents precipitation, a solvent ratio that reduces injection force, or a vehicle system that achieves a defined pharmacokinetic profile.

When does testosterone cypionate lose exclusivity?

Testosterone cypionate lost meaningful molecule-level exclusivity decades ago. Depo-Testosterone is an established reference product, and generic testosterone cypionate injections are commercially available in the United States.

There is no current biosimilar exclusivity issue. The main regulatory barriers are sameness requirements for ANDA products, controlled-substance compliance, sterile manufacturing, and product-specific formulation or device patents.

Paragraph IV challenges

A Paragraph IV certification is relevant when an ANDA applicant asserts that a listed patent is invalid, unenforceable, or will not be infringed. For a legacy testosterone cypionate injection, Paragraph IV risk is likely to focus on:

• Formulation patents
• Device patents
• Method-of-use patents
• Manufacturing patents
• Patents associated with a newer 505(b)(2) product rather than the old reference product

A generic applicant may instead use a Paragraph III certification, wait for patent expiration, or certify that no relevant patent is listed. The commercial significance depends on the specific Orange Book entry and the scope of any asserted claims.

What formulation patents are available for testosterone cypionate?

Potential claim areas include the following.

Oil composition claims

A patent could claim testosterone cypionate with a selected oil, co-solvent, antioxidant, and concentration range. Broad claims are exposed to prior art. Narrow claims can be stronger if they demonstrate unexpected solubility, stability, or injection performance.

Subcutaneous administration claims

Subcutaneous testosterone cypionate may support differentiation if the formulation permits a lower injection volume or improved tolerability. Protection would need to cover the formulation, dose, concentration, route, and patient population in a manner that avoids routine clinical practice prior art.

Prefilled syringe and autoinjector claims

Device claims can protect:

• Syringe materials
• Needle gauge
• Injection-force control
• Temperature compensation
• Plunger and stopper design
• Dose delivery
• Product-device compatibility

Device protection may be more defensible than a basic oil formulation, but commercial value depends on patient adoption and reimbursement.

Manufacturing-process claims

Manufacturing opportunities include:

• Removal of degradation products
• Control of testosterone cypionate related substances
• Sterile filtration or aseptic filling
• Crystallization and particle control
• Improved dissolution procedures
• Reduced oxygen exposure
• Container closure optimization

Process patents are useful where they reduce batch failures or enable a concentration that competitors cannot reliably manufacture.

How does testosterone cypionate compare with competing testosterone products?

Product	Dosage form	Main differentiation	Excipient opportunity
Testosterone cypionate	Oil-based IM injection	Established depot; widely genericized	Lower viscosity, subcutaneous use, prefilled delivery
Testosterone enanthate	Oil-based IM or SC injection	Similar replacement market	Vehicle and device differentiation
Testosterone undecanoate	Long-acting injection or oral product	Longer dosing interval or oral delivery	Depot control, tolerability, administration logistics
Transdermal gel	Topical gel	Noninjectable dosing	Absorption enhancers, transfer reduction, packaging
Transdermal patch	Patch	Continuous delivery	Adhesion, irritation, controlled release
Pellets	Subcutaneous implant	Long duration	Implant matrix and insertion system
Nasal testosterone	Intranasal delivery	Noninjectable route	Mucoadhesion and dosing precision

Testosterone cypionate remains attractive where cost and established clinical use dominate. It is less differentiated on convenience than long-acting testosterone undecanoate, topical products, or implants. Its lower cost creates a difficult premium-pricing environment unless the new product improves administration or reduces adverse local effects.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can pursue platform opportunities rather than a single testosterone product.

Injectable lipid platforms

A supplier with a validated parenteral lipid system could target testosterone cypionate, testosterone enanthate, nandrolone esters, and other poorly water-soluble depot injectables. The platform value increases if it provides:

• Lower viscosity
• Improved oxidative stability
• Consistent fatty-acid composition
• Global regulatory documentation
• Ready-made DMF support
• Compatibility with prefilled devices

Custom co-solvent systems

A proprietary solvent blend could support higher drug loading or smaller injection volumes. Commercial protection would depend on formulation know-how, regulatory documentation, and supply agreements, not only on patent claims.

Antioxidant and oxygen-control systems

Lipid oxidation can generate impurities, color changes, and stability failures. Suppliers can commercialize low-peroxide oils, antioxidant systems, nitrogen-purged packaging, and container closure combinations. The most defensible claims would link the system to impurity reduction over the labeled shelf life.

Device-compatible excipient systems

A vehicle optimized for autoinjectors or high-resistance syringes could command a premium if it reduces injection force without compromising depot release. This opportunity requires joint development with the device manufacturer.

What generic entry risks exist?

Generic entry risk is high for standard 100 mg/mL and 200 mg/mL testosterone cypionate injections. The active ingredient is old, the dosage form is established, and multiple manufacturers can use known oil-based technologies.

Risk is lower for a differentiated product that depends on:

• A novel subcutaneous formulation
• A proprietary injection device
• A clinically supported pharmacokinetic profile
• A manufacturing process that produces a distinct impurity profile
• A formulation with a defined tolerability advantage

The main commercial risk is that a new product may improve technical performance without generating enough clinical or reimbursement value to offset development and manufacturing costs.

What regulatory barriers affect a new testosterone cypionate product?

A sponsor selecting the ANDA route must generally match the reference product in active ingredient, dosage form, strength, route, and key performance characteristics. A materially different excipient system may require a 505(b)(2) application rather than an ANDA.

Important development requirements include:

• Sterility assurance
• Particulate control
• Endotoxin limits
• Container closure integrity
• Extractables and leachables
• Long-term and accelerated stability
• Local tolerability
• Pharmacokinetic bridging
• Controlled-substance registration and distribution controls
• Human factors validation for self-administration devices

A novel excipient without adequate parenteral precedent can create a regulatory burden disproportionate to the size of the testosterone market.

What licensing and partnership opportunities exist?

The most practical licensing structures involve:

1. An excipient supplier licensing a proprietary oil or solvent system to a generic manufacturer.
2. A specialty pharmaceutical company combining a testosterone cypionate formulation with a prefilled syringe or autoinjector.
3. A contract development and manufacturing organization providing a complete sterile injectable platform.
4. A device company licensing a low-force delivery system to an established testosterone marketer.
5. A 505(b)(2) sponsor partnering with a testosterone franchise owner for clinical development and commercialization.

Licensing value depends on freedom to operate, regulatory precedent, reproducibility at commercial scale, and evidence of improved injection performance. A formulation patent without reliable manufacturing data has limited transaction value.

How strong is the testosterone cypionate patent estate?

The estate is weak for the active ingredient and conventional oil injection, but it can be moderate for narrow formulation, device, and manufacturing inventions.

Asset type	Relative protection
Testosterone cypionate molecule	Very weak; historical protection expired
Standard cottonseed-oil injection	Weak
Alternative oil vehicle	Low to moderate, depending on claim specificity
Defined low-viscosity formulation	Moderate if supported by data
Subcutaneous product	Moderate to strong if clinically differentiated
Prefilled syringe or autoinjector	Moderate, subject to device prior art
Manufacturing impurity-control process	Moderate where process is difficult to design around
Brand and supply reliability	Commercial value without patent exclusivity

Key Takeaways

• Testosterone cypionate is a mature, genericized injectable with no meaningful molecule-level exclusivity.
• The reference product uses an oil vehicle with benzyl benzoate; excipient innovation should focus on viscosity, tolerability, stability, and delivery.
• Lower-viscosity formulations and subcutaneous administration offer the clearest product opportunities.
• Preservative-free vials, prefilled syringes, and autoinjectors can support commercial differentiation.
• Conventional oil-composition patents face substantial prior-art exposure.
• Manufacturing, device, and formulation claims are more defensible when linked to measurable performance data.
• Standard testosterone cypionate products face high generic-entry risk and limited premium-pricing power.
• A materially different product may require a 505(b)(2) application rather than an ANDA.
• Biosimilar strategy is irrelevant because testosterone cypionate is a small-molecule drug.
• Excipient suppliers can create value through validated lipid platforms, solvent systems, oxidation control, and device-compatible formulations.

FAQs

Can testosterone cypionate be formulated without cottonseed oil?

Yes. Sesame oil, medium-chain triglycerides, ethyl oleate, and other parenteral lipid vehicles may be evaluated, subject to solubility, stability, tolerability, and regulatory precedent.

Is benzyl benzoate necessary in testosterone cypionate injections?

Not necessarily. Its removal or reduction is technically possible if the alternative formulation maintains drug solubility and shelf-life stability without unacceptable injection-site reactions.

Can testosterone cypionate be administered subcutaneously?

Some formulations and clinical practices support subcutaneous administration, but a commercial subcutaneous product would require formulation, device, dosing, and regulatory support appropriate to the intended label.

Does a new testosterone cypionate excipient create new market exclusivity?

An excipient can support patent protection or regulatory differentiation, but exclusivity depends on the claim scope, prior art, regulatory pathway, and whether competitors can design around the formulation.

Which opportunity has the strongest commercial potential?

A low-viscosity, preservative-free, prefilled subcutaneous product has the strongest combined differentiation potential, provided it demonstrates reliable dosing, acceptable local tolerability, and a commercially viable manufacturing cost.

References

1. U.S. Food and Drug Administration. (n.d.). Depo-Testosterone (testosterone cypionate) injection prescribing information. Pfizer Inc.
2. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database.
3. U.S. Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book.
4. United States Patent and Trademark Office. (n.d.). Patent Center and Patent Public Search.
5. United States Pharmacopeia. (n.d.). United States Pharmacopeia and National Formulary.
6. U.S. Drug Enforcement Administration. (n.d.). Controlled substances schedules.